Captrust Financial Advisors Has $2.32 Million Stake in Solventum Co. (NYSE:SOLV)

Captrust Financial Advisors raised its stake in Solventum Co. (NYSE:SOLV) by 43.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,165 shares of the company’s stock after acquiring an additional 10,611 shares during the quarter. Captrust Financial Advisors’ holdings in Solventum were worth $2,323,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Stonebridge Financial Group LLC bought a new stake in Solventum during the 4th quarter worth $26,000. Crews Bank & Trust acquired a new stake in shares of Solventum during the fourth quarter valued at about $32,000. Synergy Asset Management LLC acquired a new stake in shares of Solventum during the fourth quarter valued at about $35,000. Spire Wealth Management bought a new stake in shares of Solventum during the fourth quarter worth about $37,000. Finally, Global Trust Asset Management LLC increased its stake in shares of Solventum by 137.5% in the fourth quarter. Global Trust Asset Management LLC now owns 570 shares of the company’s stock valued at $38,000 after buying an additional 330 shares during the period.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SOLV. Mizuho raised their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. The Goldman Sachs Group raised their price target on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Bank of America lifted their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, February 26th. Piper Sandler decreased their price objective on Solventum from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Friday. Finally, Morgan Stanley lifted their target price on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Solventum currently has an average rating of “Hold” and an average price target of $79.00.

Solventum Trading Up 5.4%

SOLV opened at $70.22 on Monday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92. The company has a fifty day moving average of $70.17 and a 200-day moving average of $71.26. The stock has a market cap of $12.15 billion and a PE ratio of 25.53. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.15. The business had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.02 billion. The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.08 earnings per share. On average, sell-side analysts predict that Solventum Co. will post 6.58 EPS for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.